You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Around the Region

Biogen’s Hemophilia B drug advances

Biogen Idec Inc. reported Monday that the Food and Drug Administration has accepted­ its biologics license application for marketing approval for a fusion protein that would be used to treat hemophilia B.

The FDA granted the Weston company a standard review timeline, Biogen Idec added in a news release.

Continue reading below

Recombinant FIXFc is the first product candidate in a new class of long-lasting clotting factor therapies being developed with the goal of reducing the burden of treatment for hemophilia B, the company said.

“We are encouraged by the FDA’s acceptance of our application, as we believe rFIXFc has the potential to transform the care of hemophilia B by ­allowing for less frequent injections and helping patients to maintain low annualized bleeding rates,” Glenn Pierce, senior vice president of Global Medical Affairs and chief medical officer of Biogen Idec’s hemophilia­ therapeutic area, said in a statement.

“We are working with the FDA to bring the first major treatment advance for the ­hemophilia B community in 15 years.”

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of